Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwMPN 2026 | Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses longer-term follow-up from the Phase III MANIFEST-2 trial (NCT04603495) evaluating combination therapy in patients with myelofibrosis. He highlights the durability of spleen volume reduction at 96 weeks and the importance of sustained treatment responses beyond the primary 24-week endpoint, with further follow-up expected at 144 weeks. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yeah, I mean, the only thing I would like to add about MANIFEST-2, because sometimes I think it’s easy to forget about a study that completed its primary endpoint, but that study has continued to be followed out. And I just want to impress upon the viewers that that’s still the largest upfront randomized prospective study with this kind of follow-up. It’s going to be week 144 soon...

Yeah, I mean, the only thing I would like to add about MANIFEST-2, because sometimes I think it’s easy to forget about a study that completed its primary endpoint, but that study has continued to be followed out. And I just want to impress upon the viewers that that’s still the largest upfront randomized prospective study with this kind of follow-up. It’s going to be week 144 soon. That’s a wealth of information and data. And what you see already at 96 weeks is the durability of spleen response. So although the primary data set that the core data at week 24 showed doubling of SVR and a two-point difference in that absolute change in TSS that was just barely statistical or just missed statistical significance. I would argue it’s the durability of that spleen response that probably is the most meaningful part of that data set in the longer-term follow-up. Because the short-term follow-up at 24 weeks is a regulatory endpoint. But what really matters when you treat the patients is can you maintain that response? Because we have five different data sets at this point that tell us that if you lose that response and come off treatment, your outcome is poor. So the fact that you see this durability at 96 weeks and we’re going to see 144 weeks, that speaks volumes. And I think that still makes Palbociclib an important agent in clinical development.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.